Medical College of Wisconsin/ Froedtert Hospital
Welcome,         Profile    Billing    Logout  
 11 Trials 
13 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
George, Ben
GRANITE, NCT05141721: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Active, not recruiting
2/3
700
US
GRT-C901, GRT-R902, Atezolizumab, Tecentriq, Ipilimumab, Yervoy, Fluoropyrimidine plus leucovorin, Xeloda, Bevacizumab, Avastin
Gritstone bio, Inc.
Colorectal Neoplasms
03/27
03/27
SEQUEL, NCT04069273: Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

Recruiting
2
58
US
Pembrolizumab Monotherapy, Keytruda, Ramucirumab, Cyramza, Paclitaxel, Taxol
Harry H Yoon, Merck Sharp & Dohme LLC, Mayo Clinic
Gastric Cancer, GastroEsophageal Cancer, Adenocarcinoma
06/25
12/25
SURPASS-2, NCT04752358 / 2020-005802-24: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers

Terminated
2
3
Europe, Canada, US
Autologous genetically modified ADP-A2M4CD8 cells
Adaptimmune, ICON plc
Esophageal Cancer, Esophagogastric Junction Cancer
06/23
12/23
AMPLIFY-7P, NCT05726864: A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

Recruiting
1/2
156
US
ELI-002 7P
Elicio Therapeutics
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12A, KRAS G12C, KRAS G12S, KRAS G13D, NRAS G12D, NRAS G12R, NRAS G12V, NRAS G12C, NRAS G12S
11/26
11/26
NCT04250597: Study of GNX102 in Patients With Advanced Solid Tumors

Terminated
1
46
US, RoW
GNX102
GlycoNex, Inc.
Solid Tumor, Metastatic Cancer, Advanced Cancer, Unresectable Solid Neoplasm
07/23
07/23
NCT03604783: Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors

Terminated
1
74
US
TP-1287
Sumitomo Pharma America, Inc.
Advanced Solid Tumors, Sarcoma, Ewing Sarcoma, Dedifferentiated Liposarcoma, Synovial Sarcoma
01/24
01/24
White, Sarah B
#HOPE4LIVER US, NCT04572633: The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy

Active, not recruiting
N/A
47
US
HistoSonics System, Histotripsy
HistoSonics, Inc.
Liver Neoplasms, Hepatocellular Carcinoma, Liver Metastases
01/23
07/26
Zindars, Stacey
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Calendar Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1144
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
SEQUEL, NCT04069273: Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

Recruiting
2
58
US
Pembrolizumab Monotherapy, Keytruda, Ramucirumab, Cyramza, Paclitaxel, Taxol
Harry H Yoon, Merck Sharp & Dohme LLC, Mayo Clinic
Gastric Cancer, GastroEsophageal Cancer, Adenocarcinoma
06/25
12/25
ABATE, NCT04289779: Study of CAbozantinib in Combination With AtezolizumaB for Muscle-Invasive BladdEr Cancer

Recruiting
2
46
US
Cabozantinib, cabometyx, Atezolizumab, Tecentriq, Cystectomy
Deepak Kilari, Exelixis, Genentech, Inc., Medical College of Wisconsin
Bladder Cancer
05/24
05/25
ACCRU-GI-2008, NCT05168163: Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Recruiting
2
122
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Cabozantinib, Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080
Academic and Community Cancer Research United, National Cancer Institute (NCI), Genentech, Inc.
Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
12/24
12/26
Bolser, Dawn
GRANITE, NCT05141721: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Active, not recruiting
2/3
700
US
GRT-C901, GRT-R902, Atezolizumab, Tecentriq, Ipilimumab, Yervoy, Fluoropyrimidine plus leucovorin, Xeloda, Bevacizumab, Avastin
Gritstone bio, Inc.
Colorectal Neoplasms
03/27
03/27
ACCRU-GI-2008, NCT05168163: Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Recruiting
2
122
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Cabozantinib, Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080
Academic and Community Cancer Research United, National Cancer Institute (NCI), Genentech, Inc.
Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
12/24
12/26

Download Options